弥漫性大B细胞淋巴瘤
伊布替尼
耐火材料(行星科学)
肿瘤科
美罗华
内科学
作者
Patrick M. Reagan,Jonathan W. Friedberg
出处
期刊:Future Oncology
[Future Medicine]
日期:2021-04-01
卷期号:17 (11): 1269-1283
被引量:18
标识
DOI:10.2217/fon-2020-0291
摘要
Axicabtagene ciloleucel and brexucabtagene autoleucel are anti-CD19 T-cell therapies that utilize the same second-generation chimeric antigen receptor with a CD28 costimulatory subunit. They have demonstrated high rates of response in high-risk patients with relapsed and refractory B-cell malignancies in multicenter clinical trials, including diffuse large B-cell and mantle cell lymphomas. The high clinical activity has led to the US FDA approval of axicabtagene ciloleucel for diffuse large B-cell lymphoma, and brexucabtagene autoleucel for mantle cell lymphoma. While they are highly effective, they have significant toxicities, including cytokine release syndrome and neurologic toxicities, which can be severe and require specialized management. This review will discuss the development, efficacy and safety of axicabtagene ciloleucel and brexucabtagene autoleucel in B-cell lymphomas.
科研通智能强力驱动
Strongly Powered by AbleSci AI